Dramatic polarization in genitourinary expert opinions regarding the clinical utility of positron emission tomography (PET) imaging in prostate cancer.
Positron-Emission Tomography
Prostatic Neoplasms
Radiotherapy
Journal
International braz j urol : official journal of the Brazilian Society of Urology
ISSN: 1677-6119
Titre abrégé: Int Braz J Urol
Pays: Brazil
ID NLM: 101158091
Informations de publication
Date de publication:
Historique:
received:
21
03
2018
accepted:
29
09
2018
pubmed:
7
12
2018
medline:
25
6
2019
entrez:
7
12
2018
Statut:
ppublish
Résumé
To ascertain the opinions of North American genitourinary (GU) experts regarding inclusion of technologies such as prostate - specific membrane antigen (PSMA) and C - 11 choline positron emission tomography (PET) into routine practice. A survey was distributed to North American GU experts. Questions pertained to the role of PSMA and C - 11 PET in PCa management. Participants were categorized as "supporters" or "opponents" of incorporation of novel imaging techniques. Opinions were correlated with practice patterns. Response rate was 54% and we analyzed 42 radiation oncologist respondents. 17 participants (40%) have been in practice for > 20 years and 38 (90%) practice at an academic center. 24 (57%) were supporters of PSMA and 29 (69%) were supporters of C - 11. Supporters were more likely to treat pelvic nodes (88% vs. 56%, p < 01) and trended to be more likely to treat patients with moderate or extreme hypofractionation (58% vs. 28%, p = 065). Supporters trended to be more likely to offer brachytherapy boost (55% vs. 23%, p = 09), favor initial observation and early salvage over adjuvant radiation (77% vs. 55%, p = 09), and to consider themselves expert brachytherapists (69% vs. 39%, p = 09). There is a polarization among GU radiation oncology experts regarding novel imaging techniques. A correlation emerged between support of novel imaging and adoption of treatment approaches that are clinically superior or less expensive. Pre - existing biases among GU experts on national treatment - decision panels and leaders of cooperative group studies may affect the design of future studies and influence the adoption of these technologies in clinical practice.
Identifiants
pubmed: 30521167
doi: 10.1590/S1677-5538.IBJU.2018.0208
pii: IBJU20180208
pmc: PMC6442122
doi:
Substances chimiques
Antigens, Surface
0
Radiopharmaceuticals
0
Choline
N91BDP6H0X
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
23-31Informations de copyright
Copyright® by the International Brazilian Journal of Urology.
Déclaration de conflit d'intérêts
Conflict of interest: None declared.
Références
J Urol. 2004 Jun;171(6 Pt 1):2122-7
pubmed: 15126770
Radiother Oncol. 2007 Aug;84(2):114-20
pubmed: 17531335
Int J Radiat Oncol Biol Phys. 2007 Nov 1;69(3):646-55
pubmed: 17531401
J Clin Oncol. 2007 Dec 1;25(34):5366-73
pubmed: 18048817
Curr Opin Urol. 2008 Jan;18(1):87-97
pubmed: 18090496
JAMA. 2008 Jun 18;299(23):2760-9
pubmed: 18560003
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Urology. 2009 Sep;74(3):643-7
pubmed: 19501891
Ann Nucl Med. 2011 Jul;25(6):414-8
pubmed: 21409348
BJU Int. 2012 Dec;110(11):1709-13
pubmed: 22934913
Clin Nucl Med. 2013 May;38(5):305-14
pubmed: 23486334
Radiother Oncol. 2014 Jan;110(1):45-54
pubmed: 23993400
Eur J Nucl Med Mol Imaging. 2014 Jul;41(7):1280-92
pubmed: 24577951
J Urol. 2015 Dec;194(6):1624-30
pubmed: 26165583
Eur Urol. 2016 Jan;69(1):9-12
pubmed: 26189689
Prostate. 2015 Dec;75(16):1934-40
pubmed: 26356236
Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):55-69
pubmed: 26450693
Theranostics. 2015 Oct 18;5(12):1388-401
pubmed: 26681984
J Nucl Med. 2016 Apr;57(4):563-7
pubmed: 26769858
J Clin Oncol. 2016 Jul 10;34(20):2325-32
pubmed: 27044935
Prostate Cancer Prostatic Dis. 2016 Sep;19(3):223-30
pubmed: 27136743
Eur Urol. 2017 Jun;71(6):886-893
pubmed: 27484843
Int J Radiat Oncol Biol Phys. 2017 Feb 1;97(2):347-354
pubmed: 28068243
Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):275-285
pubmed: 28262473
J Clin Oncol. 2017 Jun 10;35(17):1884-1890
pubmed: 28296582
Pract Radiat Oncol. 2018 Jan - Feb;8(1):28-39
pubmed: 29037965
Clin Genitourin Cancer. 2018 Apr;16(2):e323-e325
pubmed: 29174501